The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Superior therapy response predictions for patients with pancreatic cancer (PDAC) using Cellworks Singula: MyCare-009-05.
 
Gordon Taylor Moffat
No Relationships to Disclose
 
Drew Watson
Employment - CellMax Life; NephroSant
Leadership - NephroSant
Stock and Other Ownership Interests - CellMax Life; Exact Sciences; NephroSant; Telomere Diagnostics
Consulting or Advisory Role - CellMax Life; Cellworks; Telomere Diagnostics
 
Shweta Kapoor
Employment - Cellworks
 
Kunal Ghosh Ghosh Roy
Employment - Cellworks
 
Rajan Parashar
Employment - Cellworks
 
Aftab Alam
Employment - Cellworks
 
Aktar Alam
Employment - Cellworks
 
Anuj Tyagi
Employment - Cellworks
 
Divya Singh
Employment - Cellworks
 
Pallavi Kumari
Employment - Cellworks
 
Nikita Ray Choudhary
Employment - Cellworks
 
Neha Gupta
Employment - Cellworks
 
Preethi Elangovan
Employment - Cellworks
 
Rema Mandal
Employment - Cellworks
 
Vijayashree P S
Employment - Cellworks
 
Prashant Nair
Employment - Cellworks
 
Zakir Husain
Employment - Cellworks
 
Diwyanshu Sahu
Employment - Cellworks
 
Nirjhar Mundkur
Employment - Cellworks
Travel, Accommodations, Expenses - Cellworks
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); AstraZeneca (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene (I); CytomX Therapeutics; Debiopharm Group (I); Debiopharm Group (I); Eisai (I); Exelixis/Ipsen (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Incyte (I); Janssen; LAM Therapeutics (I); Lilly (I); Loxo; Merck; Minapharma (I); QED Therapeutics (I); RedHill Biopharma (I); Sillajen (I); SOBI; Targovax; Yiviva (I)
Research Funding - AstraZeneca/MedImmune (Inst)